公司名稱: 金活醫藥集團有限公司 呈交日期: 2026年2月2日 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 致：香港交易及結算所有限公司 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01110 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | HKD | | 0.1 | HKD | | 1,000,000,000 | | 增加 / 減少 (-) | | | 0 | | | | HKD | | | | 本月底結存 | | | 10,000,000,000 | HKD | | 0.1 | HKD | | 1,000,000,000 | 本月 ...

Group 1 - The core point of the announcement is that King活医药 Group plans to acquire a well-known pharmaceutical company in Hong Kong for a cash consideration of HKD 66.4368 million, which will enhance its market presence and leverage the target company's brand influence for further expansion [1][2] - The acquisition price consists of HKD 41.5 million for the target company's core business and production equipment, and HKD 24.9368 million for real estate assets [1] - The chairman of King活医药 emphasized that this acquisition is a key move to enhance the health industry chain and global strategy, aligning with the company's extensive distribution network across 34 provinces and regions [2][3] Group 2 - The memorandum stipulates that King活医药 will pay a deposit of HKD 3.32184 million within five working days, which does not constitute a significant transaction under Hong Kong Stock Exchange rules [2] - Industry analysts believe that this acquisition will enrich the company's brand portfolio and strengthen its market position in Hong Kong and Macau, while also facilitating broader international market outreach [3] - The acquisition is seen as a strategic move to fill gaps in the company's pharmaceutical manufacturing capabilities and support its long-term goal of becoming a globally influential health industry platform [3]

Core Viewpoint - Kingworld Medicines Group (01110) has entered into a memorandum of understanding regarding a proposed acquisition, which is expected to be paid in cash [1] Group 1: Acquisition Details - The total consideration for the acquisition includes a base purchase price of HKD 66.4368 million, which consists of HKD 41.5 million related to the target company's business and production equipment (excluding vehicles) and HKD 24.9368 million related to real estate properties [1] - The acquisition price will also include the net book value of the target company's equipment (excluding any vehicles) at completion and the net working capital at completion, which is defined as the total of accounts receivable and inventory minus accounts payable, subject to adjustments based on audited accounts prepared in accordance with Hong Kong Financial Reporting Standards [1] - A deposit of approximately HKD 3.3218 million will be paid to the proposed seller within five business days from the signing of the memorandum of understanding [1] Group 2: Strategic Implications - The target company is registered in Hong Kong and primarily engaged in the production and sale of pharmaceuticals, operating within real estate properties [1] - The board believes that if the proposed acquisition is realized, it will enable the group to expand its footprint in the Hong Kong pharmaceutical industry, acquire valuable manufacturing assets including real estate properties, and promote the group's domestic and international business development through synergies in product distribution and operational scale [1]

Core Viewpoint - King活医药集团 (01110) has announced a proposed acquisition involving its wholly-owned subsidiary, King活医药 (BVI), which is expected to be paid in cash [1] Group 1: Acquisition Details - The total consideration for the acquisition includes a base purchase price of HKD 66.4368 million, comprising HKD 41.5 million for the target company's related business and production equipment (excluding vehicles) and HKD 24.9368 million for real estate properties [1] - The consideration will also include the net book value of the target company's equipment (excluding any vehicles) at completion and the net working capital at completion, which is defined as the total of accounts receivable and inventory minus accounts payable, subject to adjustments based on audited accounts prepared in accordance with Hong Kong Financial Reporting Standards [1] - A deposit of approximately HKD 3.3218 million will be paid to the proposed seller within five business days from the signing of the memorandum of understanding [1] Group 2: Strategic Implications - The target company is registered in Hong Kong and primarily engaged in the production and sale of pharmaceuticals, operating within real estate properties [1] - The board believes that if the proposed acquisition is realized, it will enable the group to expand its footprint in the Hong Kong pharmaceutical industry, acquire valuable manufacturing assets including real estate properties, and promote the group's domestic and international business development through synergies in product distribution and operational scale [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 自願公告 有關建議收購事項之諒解備忘錄 本公告由金活醫藥集團有限公司自願作出。 董事會欣然宣佈，於二零二六年一月二十二日（交易時段後），本公司之全資附 屬公司金活醫藥(BVI)就建議收購事項與擬定賣方及擔保人訂立諒解備忘錄。目 標公司主要從事藥品生產及銷售並持有地產物業。預計代價將以現金支付。擔 保人同意就擬定賣方履行其於諒解備忘錄項下之責任提供擔保。 自簽訂諒解備忘錄起五個營業日內，金活醫藥(BVI)將向擬定賣方支付按金 3,321,840港元。由於就支付按金而言，上市規則項下之相關百分比率均低於 5%，故訂立諒解備忘錄並不構成上市規則第十四章項下本公司之須予公佈交 易。 倘建議收購事項得以落實，則可能構成上市規則第十四章項下本公司之須予披 露交易。 董事會謹此強調，於本公告日期，金活醫藥(BVI)並未就建議收購事項與任何人 士訂立具法律約束力之協議（諒解備忘錄內有關（其中包括）按金、盡職審查、 排他 ...

Core Insights - The article highlights the successful integration of modern agriculture and global supply chains, particularly focusing on the winter availability of strawberries from Dandong, China, and cherries (referred to as "车厘子") from Chile, which cater to the Chinese New Year market demand [1][2][3] Group 1: Seasonal Availability - Strawberries, traditionally a spring fruit, are now available year-round due to advanced cultivation techniques, with Dandong farmers harvesting multiple crops from August to March [2][3] - Chilean cherries are harvested from November to February, coinciding with the winter season in the Northern Hemisphere, allowing for a continuous supply of fresh cherries during the Chinese New Year [3] Group 2: Preservation Techniques - Dandong strawberries maintain freshness through rapid cooling and cold chain logistics, with a two-hour window for pre-cooling after harvest, ensuring delivery within 48 hours [4] - Chilean cherries utilize a combination of quick cooling and modified atmosphere packaging to extend shelf life, with cherries entering ice water within 3-4 hours post-harvest [4] Group 3: Food Safety Measures - Dandong strawberries are cultivated using green farming techniques, including organic fertilizers and physical pest control, ensuring a safe product for consumers [5] - Chilean cherries adhere to strict export standards, with quality checks at both the source and upon arrival in China, providing a dual layer of safety for consumers [6] Group 4: Financial Support for Agriculture - Guangfa Bank has introduced innovative financial products to support the strawberry and cherry industries, including a specialized loan program for strawberry farmers in Dandong, with a maximum credit limit of 300,000 yuan [7] - The bank's services extend to the logistics and sales chain for Chilean cherries, facilitating timely financing for international procurement and domestic logistics [7] Group 5: Conclusion - The article emphasizes the collaborative efforts of farmers, technology, and financial institutions in ensuring the availability of fresh strawberries and cherries, showcasing a model of modern agricultural practices [8]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 金活醫藥集團有限公司 呈交日期: 2026年1月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01110 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | HKD | | 0.1 HKD | | 1,000,000,000 | | 增加 / 減少 (-) | | | 0 | | | HKD | | | | 本月底結存 | | | 10,000,000,000 | HKD | | 0.1 HKD | | 1,000,000,000 | 本月底法定/註冊股本總額： HKD 1 ...

Group 1 - The "Annual Outstanding Healthcare Enterprises" award recognizes companies in the Chinese healthcare industry that excel in innovation, technological leadership, market influence, social value, and sustainable development [4] - The award winners include Alibaba Health (00241.HK), Anxuyuan, Baize Medical (02609.HK), Gushengtang (02273.HK), Haijia Medical (06078.HK), Jinhua Medical Group (01110.HK), Kangchen Pharmaceutical (01681.HK), Ping An Good Doctor (01833.HK), Weitai Medical-B (02235.HK), and Xinwei Medical-B (06609.HK) [1] - The selection process involved quantitative data analysis and an expert review panel to determine the final results [4] Group 2 - The "Jin Ge Award" aims to create a reference for the investment community by highlighting the most valuable listed companies and unicorns in China [4] - The evaluation covers all listed companies and unicorns on the Hong Kong Stock Exchange, Shanghai Stock Exchange, Shenzhen Stock Exchange, New York Stock Exchange, American Stock Exchange, and NASDAQ [4]

Group 1 - The photovoltaic sector experienced a significant intraday surge, with the photovoltaic industry index rising by 2.06% as of 14:03, led by stocks such as Roboteam and Kstar [1] - The "anti-involution" efforts in the photovoltaic industry have begun to show results, with prices in the photovoltaic supply chain starting to recover and corporate profits improving, particularly in the upstream polysilicon segment [1] - In December, domestic polysilicon production decreased by 0.96% month-on-month, while wafer, cell, and module production saw declines of 15.95%, 12.61%, and 13.58% respectively, indicating a trend of reduced production across multiple segments of the photovoltaic supply chain [1] Group 2 - Industry insiders attribute the continued decline in production across multiple segments in December to insufficient terminal demand, suggesting that the effects of "anti-involution" will lead to a gradual price recovery in the photovoltaic industry by 2026 [1] - CITIC Construction Investment Securities noted that price control measures have led to price increases in the main supply chain since July, with the polysilicon segment returning to profitability in Q3, although there remains significant inventory pressure of approximately 460,000 tons across the industry [1] - The overall expectation is that the "anti-involution" policy will help restore profitability to reasonable levels across various segments of the photovoltaic supply chain [1]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 FF301 II. 已發行股份及/或庫存股份變動 致：香港交易及結算所有限公司 公司名稱: 金活醫藥集團有限公司 呈交日期: 2025年12月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01110 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | HKD | | 0.1 | HKD | | 1,000,000,000 | | 增加 / 減少 (-) | | | 0 | | | | HKD | | | | 本月底結存 | | | 10,000,000,000 | HKD | | 0.1 | ...